Navigation Links
Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
Date:7/22/2014

MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc (LSE: VER) and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their US prescription cough cold collaboration. Under this collaboration, POC requires the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product. As a result of achieving POC, Vernalis will make a milestone payment to Tris.

Under the deal announced in February 2012, Vernalis is paying Tris to develop up to six unique OralXR+™ based extended release liquid equivalents to existing immediate release prescription cough/cold treatments. The financial terms of this licensing deal are not disclosed.

Ian Garland, CEO of Vernalis commented "Three of our five cough cold programmes in our collaboration with Tris have now achieved proof-of-concept and for the most advanced of those programmes (Tuzistra™ XR) an NDA has already been submitted to the FDA. We are delighted with the momentum building in our Tris collaboration and are looking forward to continuing success over the remainder of the year".

Ketan Mehta, CEO of Tris commented "This is an exciting time for both our companies with the continuing progress of the prescription cough cold portfolio and we look forward to the further success of our partnership with Vernalis."

Notes to Editors

About Vernalis  
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com.

About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A.

For more information, please visit www.trispharma.com

Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.


'/>"/>
SOURCE Tris Pharma, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. ISSI Announces Fiscal 2014 Third Quarter Conference Call
2. Sono-Tek Announces Third Quarter Results
3. Uroplasty To Announce Third Quarter Fiscal 2014 Financial Results On January 23, 2014
4. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
5. The Epilepsy Market Will Grow 2 Percent Annually Through 2022 with Expanding Uptake of Third-Generation Brands
6. Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test
7. China Nepstar Chain Drugstore Reports Third Quarter 2013 Financial Results
8. Veracyte, Inc. Announces Third Quarter 2013 Financial Results
9. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
10. Bayers Third Annual Virtual Walk for Hemophilia Raises Funds, Brings Together the Hemophilia Community
11. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Many patients don,t ... their medication when a pharmacy just a few blocks ...  To alleviate this problem Medicationdiscountcard.com has created ... see exactly how much their medication will cost at ... Easy Medicationdiscountcard.com takes ...
(Date:1/19/2017)... Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... TomoTherapy® Systems continue to set the bar for excellence ... composite overall user satisfaction rating among radiation treatment delivery ... MD Buyline Market Intelligence Briefing™. The most recent ratings ... ratings among industry peers for 11 of the past ...
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. (Nasdaq: ... federal institution supporting research in Germany ... patient treatments at the University Clinic Heidelberg as part ... The MRIdian Linac program will be headed by Medical ... heads radiation oncology at the German Cancer Research Center ...
Breaking Medicine Technology:
(Date:1/21/2017)... MALO, FRANCE (PRWEB) , ... January 21, 2017 , ... ... of the Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER ... East Africa, Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates (NCMA) ... their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, ... add this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, ...
(Date:1/21/2017)... , ... January 21, 2017 , ... In the United ... individuals experience the freedom of recovery, they often feel shame for having struggled with ... stress disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” ...
(Date:1/20/2017)... ... ... ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift is easy ... wheeled out of the way and stored when not in use. It is freestanding and ... from customers into specific enhancements and created a new product that is built directly on ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
Breaking Medicine News(10 mins):